Science Advice Enables Huntington's Gene Therapy Breakthrough Treatment
Summary
NIHR, funded by the Department of Health and Social Care, supported uniQure's landmark clinical study of gene therapy AMT-130 for Huntington's disease. The Phase I/II trial showed that participants receiving higher doses experienced 75% less disease progression after three years. Around 8,000 people in the UK are living with Huntington's disease, a rare fatal condition caused by a single genetic mutation.
What changed
NIHR published a case study documenting how science advice and publicly funded research infrastructure enabled a landmark gene therapy trial for Huntington's disease. The study tested uniQure's AMT-130, the first gene therapy for Huntington's disease, using NIHR Biomedical Research Centres, Clinical Research Facilities, and the NIHR Research Delivery Network. Results showed 75% reduction in disease progression at higher doses after three years.\n\nFor patients and families affected by Huntington's disease, this represents a significant development as the first treatment to demonstrate disease-slowing effects. The case study illustrates how coordinated research infrastructure can accelerate breakthrough treatments, potentially informing future approaches to rare disease research in the UK.
What to do next
- Monitor for updates on AMT-130 regulatory pathway
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Case study
Slowing Huntington’s disease: how science advice enabled a breakthrough treatment
A coordinated research effort shows how science advice and shared infrastructure can help turn new ideas into meaningful progress for people and communities.
From: Government Office for Science Published 5 March 2026
Around 8,000 people in the UK are living with Huntington’s disease, a rare and fatal condition caused by a single genetic mutation. Until now, there has been no treatment proven to slow its progression. Through science advice and publicly funded research infrastructure, that is beginning to change.
The National Institute for Health and Care Research (NIHR), funded by the Department of Health and Social Care, supported a landmark clinical study into a new gene therapy, AMT-130 – the first gene therapy to be tested in people with Huntington’s disease. The study, funded by the life sciences company uniQure, showed that participants receiving a higher dose of the treatment experienced 75% less disease progression after three years, alongside slower decline in movement and thinking. For patients and families, this represents long-awaited hope.
An NIHR Biomedical Research Centre and NIHR Clinical Research Facility provided expert scientific advice, specialist NHS facilities, and skilled research staff. The NIHR Research Delivery Network provided further research staff and supported a long-term observational research study, which provided a suitable comparison group of those with Huntington’s who were not receiving the treatment, ensuring the results were robust.
This study is one of nearly 18,000 projects enabled by NIHR research infrastructure in a single year. By bringing together trusted science advice, the NHS, and industry, NIHR helps turn cutting-edge ideas into real-world treatments that improves the health and wealth of the nation. It also strengthens the UK ’s position as a global leader in life sciences and innovation.
This is science advice in action – supporting better decisions, safer research, and breakthroughs that can save lives. It Celebrates Science Advice, highlighting how evidence and expertise underpin progress across public services and deliver real benefits for people and communities.
Related content
Related changes
Get daily alerts for Uk Government Office For Science
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from GO-Science.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Uk Government Office For Science publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.